GRI Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRI research report →
Companywww.gribio.com
GRI Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
- CEO
- W. Marc Hertz
- IPO
- 2023
- Employees
- 3
- HQ
- La Jolla, CA, US
Price Chart
Valuation
- Market Cap
- $197.63K
- P/E
- -0.25
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- 0.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -199.52%
- ROIC
- -103.07%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-11,956,000 · -45.68%
- EPS
- $-121.80 · 92.12%
- Op Income
- $-11,977,000
- FCF YoY
- -18.33%
Performance & Tape
- 52W High
- $80.36
- 52W Low
- $1.97
- 50D MA
- $2.40
- 200D MA
- $24.45
- Beta
- -1.22
- Avg Volume
- 81.93K
Get TickerSpark's AI analysis on GRI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 25 | Kelly Leanne | other | 43,222 |
| Sep 18, 25 | Szekeres David Leslie | other | 39,897 |
| Sep 18, 25 | Baker David Charles | other | 23,605 |
| Sep 18, 25 | SIMPSON CAMILLA V | other | 23,605 |
| Sep 18, 25 | Chaturvedi Vipin | other | 43,222 |
| Sep 18, 25 | Rongen Roelof | other | 23,605 |
| Sep 18, 25 | Hertz Walter Marc | other | 103,067 |
| Aug 26, 25 | Hertz Walter Marc | other | 26,688 |
| Aug 26, 25 | Szekeres David Leslie | other | 10,276 |
| Aug 26, 25 | Baker David Charles | other | 5,994 |
Our GRI Coverage
We haven't published any research on GRI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GRI Report →